Differential cytolocation and functional assays of the two major SLC30A8 (ZnT8) isoforms by Carvalho, Sandra et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.jtemb.2017.06.001
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Carvalho, S., Molina-López, J., Parsons, D., Corpe, C., Maret, W., & Hogstrand, C. (2017). Differential
cytolocation and functional assays of the two major SLC30A8 (ZnT8) isoforms. Journal of Trace Elements in
Medicine and Biology, 44, 116-124. https://doi.org/10.1016/j.jtemb.2017.06.001
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
Title: Differential cytolocation and functional assays of the
two major SLC30A8 (ZnT8) isoforms
Authors: Sandra Carvalho, Jorge Molina-Lo´pez, Douglas
Parsons, Christopher Corpe, Wolfgang Maret, Christer
Hogstrand
PII: S0946-672X(17)30066-4
DOI: http://dx.doi.org/doi:10.1016/j.jtemb.2017.06.001
Reference: JTEMB 25938
To appear in:
Received date: 5-2-2017
Revised date: 2-6-2017
Accepted date: 6-6-2017
Please cite this article as: Carvalho Sandra, Molina-Lo´pez Jorge, Parsons Douglas,
Corpe Christopher, Maret Wolfgang, Hogstrand Christer.Differential cytolocation and
functional assays of the two major SLC30A8 (ZnT8) isoforms.Journal of Trace
Elements in Medicine and Biology http://dx.doi.org/10.1016/j.jtemb.2017.06.001
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
 1 
 
Differential cytolocation and functional assays of the two major SLC30A8 (ZnT8) isoforms 
 
Sandra Carvalho1, Jorge Molina-López1,2, Douglas Parsons1, Christopher Corpe1, Wolfgang Maret1,*, 
Christer Hogstrand1 
1Diabetes and Nutritional Sciences Division, Faculty of Life Sciences and Medicine, King’s College 
London, London, UK 
2Department of Physiology, Institute of Nutrition and Food Technology “José Mataix”, University of 
Granada, Spain 
 
*Corresponding author 
FWB 3.79 
150 Stamford Street 
London SE1 9NH 
United Kingdom 
+44 (0)20 7848 4264 
wolfgang.maret@kcl.ac.uk  
 
Highlights: 
 Two isoforms (splice variants) of ZnT8 differ in subcellular localization in human cells. 
 Surface localization of ZnT8 in X. laevis oocytes allowed developing a 65Zn transport 
assay. 
 The amino acid at position 325, responsible for the R and W variants, is poorly 
conserved. 
 Differential localization of isoforms may be important for ZnT8 function and 
antigenicity 
 
Abstract. The non-synonymous single nucleotide polymorphism (SNP) rs13266634 in human 
zinc transporter 8, ZnT8 (SLC30A8), leads to a R325 variant, which is associated with an 
increased risk of developing Type 2 Diabetes (T2D). Although the molecular details remain 
unknown, the mutation is thought to alter the kinetics of zinc transport into insulin granules 
in pancreatic β-cells. Nevertheless, analysis of ZnT8 sequences from several animals shows 
that the amino acid at position 325 is poorly conserved. Apart from this particular SNP, 
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human ZnT8 also has two isoforms (splice variants) that differ in length regarding a 49 amino 
acid N-terminal extension. When expressed in human embryonic kidney (HEK293) cells, the 
long isoform was present in the plasma membrane in addition to internal membranes, 
whereas the short isoform was localized mostly to internal membranes. Our observation 
that human ZnT8 variants and isoforms expressed in Xenopus laevis oocytes are all localized 
at the cell surface allowed us to develop a zinc transport assay using the radioactive isotope 
65Zn. We found no detectable differences in zinc transport between W and R variants and no 
statistically significant differences between long and short isoforms of the W325 variant. Our 
findings of different cytolocation of ZnT8 isoforms could be relevant for β-cell zinc 
metabolism in health and disease. 
 
Keywords: Zinc, vesicular CDF transporters, ZnT8, β-cell insulin granules, diabetes 
 
Introduction 
Zinc is a micronutrient that is essential for virtually all biological processes [1]. 
Acquisition, storage, and efflux of zinc are orchestrated by transporters belonging to two 
families: the Zrt/Irt-like Transporter (ZIP; also known as SLC39A) family, which mediates the 
flux of zinc from the extracellular environment or from the lumen of organelles into the 
cytosol, and the Zinc Transporter (ZnT; also known as SLC30A) family, which is part of the 
larger Cation Diffusion Facilitator (CDF) family and mediates the flux of the metal ions away 
from the cytosol [2, 3]. The concerted actions of these transporters are a prerequisite for the 
control of zinc homeostasis. Dysfunctional ZIP or CDF members lead to disorders, such as 
Acrodermatitis Enteropathica, transient neonatal zinc deficiency, Spondylocheirodysplastic 
Ehlers-Danlos Syndrome, Type 2 Diabetes (T2D), and many others [4, 5]. 
Zinc transporter 8 (ZnT8) is a member of the CDF family of proteins and expressed 
almost exclusively in pancreatic α- and β-cells [6-8] and in kidneys [4, 9]. In pancreatic β-
cells, ZnT8 transports zinc from the cytosol into the lumen of insulin granules [10], where 
zinc assists insulin packaging into hexamers with two bound zinc ions and one bound calcium 
ion. Besides being located mainly in the membrane of insulin granules in β-cells, ZnT8 is also 
observed in the plasma membrane and in its proximity in the β-cell-derived INS-1E cell line 
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[11, 12]. Each functional ZnT8 transporter molecule is a dimer of two identical monomers. 
Each monomer has six transmembrane domains with N- and C-termini facing the cytosol. 
The C-terminal domain has a metallochaperone-like fold. There are two splice variants 
(isoforms) of human ZnT8 as shown by quantification of their respective transcripts in an 
RNAseq analysis of human pancreatic islets [13]. These isoforms differ at the N-terminus, 
where one of them has a 49-amino acid extension. The longer isoform (Q8IWU4_1) has 369 
amino acid residues and the shorter isoform (Q8IWU4_2) has 320, with relative transcript 
abundances of about 70% and 30%, respectively [13]. The majority of the studies so far have 
focused on the longer isoform. Whether or not the two isoforms differ functionally is not 
known.  
Genome-wide association studies (GWAS) showed that carriers with the non-
synonymous single nucleotide polymorphism (SNP) rs13266634 in human ZnT8 have an 
increased risk of developing T2D [14-16]. This SNP results in an arginine (R) instead of a 
tryptophan (W) at position 325 in the C-terminus (numbering for the long isoform). The 
functional association of R325 with an increased risk of T2D is unclear. One hypothesis is 
that ZnT8 carrying R325 has altered zinc transport activity that affects the synthesis, storage, 
and/or secretion of insulin. Fluorescence- and radioactivity-based studies on the rodent 
pancreatic β-cell lines MIN6 and INS-1E overexpressing W or R variants of ZnT8 showed 
lower transport activity of the R325 variant [7, 17]. In contrast, a recent study found the 
R325 variant to be more active, both in HEK293 cells and when incorporated into an artificial 
proteoliposome bilayer [18]. These opposite outcomes likely reflect conditionality of ZnT8 
function, and whilst these experimental models are useful, they have drawbacks in the 
interpretation of the results. It is virtually impossible to control transport conditions in 
transfected cells where ZnT8 moves zinc ions into vesicles. In contrast, experimental 
conditions can be tightly controlled in transport assays utilizing proteoliposomes, but such a 
system is highly artificial when compared to a cellular environment. The conditional Km value 
of ZnT8 for Zn2+ (>100 µM) in artificial proteoliposomes [18] is at least 250,000 times higher 
than the resting cytosolic [Zn2+] in β-cells [19]. Therefore, there is a need to address the ZnT8 
structure-function relationships in alternative assay systems. 
The main objective of the present study was to establish a cell-based zinc transport 
assay that would allow comparing the kinetic properties of human ZnT8 variants and 
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isoforms. Heterologous expression in Xenopus laevis oocytes seems to be well suited as no 
net zinc transport is observed at the latest stage of oocyte development [20]. Frog oocytes 
have been employed for measuring the zinc transport activity of ZnT5 [21]. Remarkably, 
despite being a vesicular transporter, we find ZnT8 proteins expressed in oocytes at the 
surface and active in zinc transport. Expression of ZnT8 isoforms in human embryonic kidney 
(HEK293) cells confirmed the differential sub-cellular localization of the two isoforms, 
indicating potential for differential physiological functions. This experimental system, 
therefore, is expected to provide critical information about the zinc transport activity of the 
class of vesicular zinc transporters (ZnT2-4), the zinc transport activity of which has not been 
investigated.  
 
Materials and Methods 
Plasmid construction 
Genes of V5-tagged ZnT8 isoforms (R variant) were synthesized (Biomatik, 
Wilmington, DE, USA) and cloned in pcDNA3.1(+) into XhoI and BamHI restriction sites. The 
long isoform, N-V5-ZnT8lg, was designed to have the V5 tag inserted after the first 49 amino 
acids. The short isoform, V5-ZnT8sh, which lacks the first 49 amino acids, had the V5 tag 
introduced at the N-terminus. The tag was, therefore, in the same position in both isoforms. 
The W variants were obtained from the above-mentioned plasmids by site-directed 
mutagenesis (Mutagenex, Suwanee, GA, USA). 
 
Expression in HEK293 cells 
HEK293 cells were cultured in DMEM (Gibco, Carlsbad, CA, USA) containing 10% heat-
inactivated FBS (Gibco), 100 U/ml penicillin (Gibco), and 100 μg/ml streptomycin (Gibco), at 
37°C with 5% CO2 in humidified atmosphere. Transient transfection of HEK293 cells with 
pcDNA3.1(+)-N-V5-ZnT8lg and pcDNA3.1(+)-V5-ZnT8sh was performed using FuGENE® HD 
(Promega, Madison, WI, USA) at a 3:1 ratio, according to manufacturer's instructions. 
Localization of tagged proteins was investigated 48 h after transfection. 
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Expression in X. laevis oocytes 
Synthesis of RNA from pcDNA3.1(+) constructs linearized with EciI was performed 
using the mMESSAGE mMACHINE/T7 RNA polymerase transcription kit (Ambion, Foster City, 
CA, USA) according to the manufacturer’s instructions. Oocytes, originating from the 
European Xenopus Resource Centre (EXRC, Portsmouth, UK), were defolliculated in two 30-
min incubations with 2 mg/mL collagenase (Sigma-Aldrich, St. Louis, MO, USA) in calcium-
free Barth’s Modified Saline (BMS; 88 mM NaCl, 1 mM KCl, 0.82 mM MgSO4, 10 mM HEPES). 
Defolliculated oocytes were then washed in complete BMS [with calcium: 0.33 mM 
Ca(NO3)2, 0.41 mM CaCl2], and stage VI oocytes were selected. Selection was based on size 
and pigmentation of the poles and equatorial band. Oocytes were left for one day in 
complete BMS supplemented with 1 mM sodium pyruvate (GE Healthcare, Chalfont St. Giles, 
UK) and 50 μg/mL tetracycline (Sigma-Aldrich), and then injected with 18 ng of cRNA and 
incubated for 3 days in fresh medium before performing radiotracer efflux assays, 
immunolocalization, and protein extraction. Non-injected oocytes were used as controls. 
 
Cell membrane biotinylation 
Biotinylation of cell membrane proteins was adapted from Carvalho et al. [22]. 
Briefly, 20 oocytes were washed twice in PBS-glucose (1 mg/mL) and incubated, for 1 h on 
ice and with constant shaking, in 1 mL of 1 mg/mL EZ-Link™ Sulfo-NHS-SS-Biotin (Thermo 
Scientific, Boston, MA, USA) prepared in PBS-glucose. The reaction was stopped by the 
addition of 500 mM glycine, pH 7.4. Cells were washed three times with PBS-glucose and 
lysed in 100 μL homogenization buffer [100 mM NaCl, 1% (v/v) Triton-X100, 20 mM Tris-HCl, 
pH 7.5] with a Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific) 
supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF). The extracts were diluted 
in 900 μL of PBS-glucose and incubated with 15 μL of streptavidin-bound Dynabeads® 
MyOne™ Streptavidin C1 (Invitrogen, Carlsbad, CA, USA), for 1 h in a rotating shaker, at 22°C. 
Beads were magnetically separated, washed four times in PBS-glucose, and resuspended in 
30 μL of 50 mM 1,4-dithiothreitol (DTT) and 4 M urea prepared in Laemmli sample buffer. 
After 2 h of incubation at room temperature, proteins were run on an SDS gel and subjected 
to western blotting. For extraction of the total protein, 10 oocytes were lysed by continuous 
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pipetting in 50 mM Tris-HCl pH 7.4, containing a cocktail of protease inhibitors. The 
suspension was spun for 2 min at 300 ×g to remove yolk proteins, and the supernatant was 
recovered. Extracts were run on an SDS gel after addition of 4 M urea and 1% (v/v) β-
mercaptoethanol in Laemmli sample buffer, without boiling or heating, and subjected to 
western blotting. Membranes from biotinylated and total extracts were hybridised with anti-
V5 antibody (ab27671, Abcam, Cambridge, UK) and re-hybridised, after stripping, with anti-
GAPDH, a cytosolic protein (mAbcam 9484, Abcam). 
 
Indirect immunofluorescence assay  
To localize ZnT8 isoforms expressed in X. laevis oocytes and in HEK293 cells, cells 
were first washed three times in PBS, fixed in 4% (w/v) paraformaldehyde and permeabilized 
with 0.1% (v/v) Triton X-100. After blocking with 1% (w/v) bovine serum albumin (BSA), cells 
were incubated with anti-V5 antibody overnight, followed by Alexa Fluor® 594-conjugated 
antibody (Molecular Probes, Carlsbad, CA, USA) for 1 h. In HEK293 cells, DNA was stained 
with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI), and the coverslips were then 
mounted in 70% (v/v) glycerol in PBS. Images of oocytes were acquired with an A1R Si MP 
Confocal Microscope (Nikon, Tokyo, Japan), and images from HEK cells were acquired with a 
Leica Confocal Microscope (Leica Microsystems, Wetzlar, Germany).  
 
65Zn efflux assays in X. laevis oocytes 
Zinc efflux in oocytes was measured after loading the cells with 65Zn (specific activity 
= 75.3 MBq/mg; Polatom, Otwock, Poland). Each oocyte was placed in a tube containing 500 
µL of efflux buffer. After 1 h at 19°C, the buffer was transferred to another tube, the oocyte 
washed with 500 µL of efflux buffer, and the medium recovered in the same tube as before. 
The radioactivity in the medium and that associated with the oocyte were measured in a γ-
counter (Beckman Coulter, Fullerton, CA, USA). Results are given as the percentage of counts 
per minute (cpm) of 65Zn in the supernatant in relation to the total cpm of injected 65Zn per 
oocyte (sum of the radioactivity in the oocyte and in the supernatant). Five control or cRNA-
injected oocytes were used per condition. The conditions tested in the efflux assays are 
shown in Table I.  
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Statistical analysis 
Data were analysed using SPSS 20.0 (IBM Corp., Armonk, NY, USA). Each efflux 
experiment was expressed as the mean value and standard deviation for descriptive 
analysis. Data distribution was tested with the Shapiro-Wilk test. One-way ANOVA or the 
Mann–Whitney test was used for normal distribution and non-normal distribution of 
variables. Bonferroni or Tamhane multiple comparison post hoc tests were used, after one-
way ANOVA, depending on the Levene’s test for the homogeneity of variances. The level of 
significance was set at 0.05.  
 
Results 
CDF members are present in Archaea, Eubacteria, and Eukaryotes, and all 
functionally characterised CDF proteins are Me2+/H+ or Me2+/K+ antiporters, transporting 
divalent metal ions from the cytosol to the lumen of organelles or to the exterior of the cell. 
In order to identify amino acids that are characteristic of vesicular transporters and for ZnT8, 
we performed a sequence alignment. Alignment of amino acidic sequences of ZnT8 from 
several vertebrate species and comparison with the sequence of YiiP from E. coli (also known 
as ferrous iron and zinc transporter, Fief) reveals a high degree of conservation in critical 
parts of the molecule (Fig. 1A). All of the sequences, except those from the frog, present the 
CDF family signature proposed by Montanini et al. [23] and derived from the multiple 
sequence alignment of characterized and hypothetical CDF members: [SC]-X-[ASG]-[LIVM]-
[LIVMTAF]-[SATG]-[DAELSTY]-[SGALFMTV]-{DKNPQR}-[HDNEL]-X3-[DH]-X2-[ASGLNTI]-X20–25-
G-X2-[KNQRSY]-X-[DEGLNPQRST], where X is any amino acid, any one of the amino acids 
shown within square brackets is possible, and none of the amino acids within braces are 
possible. Humans and rats have two ZnT8 isoforms. The amino acid sequences of the human 
ZnT8 isoforms are 100% identical except that one (Q8IWU4_1) possesses an N-terminus that 
is 49 amino acids longer; the rat isoforms also are 100% identical except for the last two 
amino acids and for the fact that one isoform has a C-terminus that is 46 amino acids longer. 
With the exception of X. tropicalis, which is predicted to have two isoforms as well, albeit 
showing some sequence variation, only one protein is predicted in all other species. The 
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amino acids important for CDF function in non-human species are all present in human ZnT8 
(Fig. 1A). Sequences from mammals also present the di-leucine motif [DE]-X3-L-[LI] (aa 269-
274) in the C-terminus.  
As expected, the regions with the highest degree of identity and similarity are the 
transmembrane domains (TMDs). Nevertheless, the N-termini show conservation and 
similarity of some amino acids among the animal ZnT8 sequences, and the region 
downstream of the last TMD, from amino acids 270 to 321 in the C-terminal domain, is 
rather highly conserved but not from amino acids 322 to 344. Additionally, there is high 
similarity among the ZnT8 sequences of mammals (humans, chimpanzees, rats, mice, and 
dogs) not only in the N-terminus but also in the region between amino acids 322 and 344. 
This grouping is in agreement with the phylogenetic tree where mammals separate from 
amphibians, birds, fish, and reptiles, and the E. coli sequence separates from all others (Fig. 
1B).  
 
Localization of V5-tagged ZnT8 in HEK293 cells 
Despite being expressed mainly in the pancreatic α- and β-cells, ZNT8 transcripts 
have also been detected in the kidneys and testes [4, 9]. To determine the localization of the 
two ZnT8 isoforms, we designed two synthetic genes from the W325 variant: one in which 
the V5 tag was inserted after the first 49 amino acids (N-V5-ZnT8lg) and the other lacking the 
first 49 amino acids and carrying the V5 tag at the N-terminus (V5-ZnT8sh) (Fig. 2). 
Therefore, both genes were tagged at the same position; the only difference being that one 
coded for a protein that is 49 amino acids shorter. The long forms carrying one of several 
different N-terminal tags were also tested but none of these produced a detectable protein, 
suggesting that ZnT8 is N-terminally cleaved. When HEK293 were transfected with plasmids 
carrying either one of the two forms the majority of cells transfected with the long isoform 
showed fluorescence at the cell membrane as well as in intracellular membranes (Fig. 3A), 
whereas the short isoform was observed primarily in intracellular membranes (Fig. 3B).  
 
Expression of ZnT8 isoforms in X. laevis oocytes 
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The X. laevis oocyte system was used to compare zinc transport activity of the two 
isoforms of human ZnT8. In order to measure zinc transport across the plasma membrane, 
these proteins are required to be expressed at the surface of the cell. Oocytes were injected 
with cRNA produced from the W325 variant of the N-V5-ZnT8lg and V5-ZnT8sh genes, and 
the expression and location of the proteins were assessed by immunofluorescence and 
western blotting of biotinylated cell-surface proteins. Non-injected oocytes were used as 
controls. Confocal imaging of whole cells demonstrated that both ZnT8 isoforms are 
expressed in the plasma membrane (Fig. 4A). In some cells, a double ring was observed, 
which could be due to ZnT8 in the cell membrane and to the high level of fluorescence of the 
yolk [24] and/or ZnT8 expression in intracellular membranes such as the ER that can contact 
the plasma membrane. Given the limiting penetration depth of the laser, we could detect 
only signals a few micrometers below the cell surface. Any expression in deeper structures 
will remain unidentified by this method. The presence of ZnT8 at the cell membrane of 
oocytes was confirmed by cell-surface biotinylation. Western blot of isolated plasma 
membrane clearly shows that both isoforms of ZnT8 are present at the surface of the 
oocytes (Fig. 4B). The higher molecular mass bands are consistent with ZnT8 dimers. As 
control for possible intracellular biotinylation, we used the cytosolic protein glyceraldehyde 
phosphate dehydrogenase (GAPDH). GAPDH was not detected in the biotinylated fraction, 
demonstrating that biotinylation occurred only at the cell membrane. Given that the number 
of oocytes used in the biotinylation protocol was twice that used in total protein extracts 
and that the intensity of the bands is lower in the biotinylated fraction than in the total 
extracts, it can be concluded that, although ZnT8 is present at the surface of oocytes, the 
majority of ZnT8 is located in intracellular membranes. Thus, the net export observed in the 
following transport assay indicates that the capacity of all intracellular zinc stores is already 
exhausted.  
 
Radiotracer transport assays in oocytes 
ZnT8 is expected to transport metal ions away from the cytosol and, therefore, out of 
the cell when present at the cell membrane. Therefore, the assays in X. laevis oocytes 
focused on the analysis of 65Zn efflux from oocytes. Radiotracer transport assays were 
 10 
 
performed three days after nano-injection of cRNA. Oocytes were loaded with 65Zn, and the 
amount of radioactivity in the supernatant assessed after 1 h.  
Among all the conditions tested, the conditions for reproducible results are: injection 
of 65Zn together with 10 mM nitrilotriacetic acid (NTA; a zinc chelator), at a pH value higher 
than 4, and an extracellular buffer without calcium and with 1 mM NTA, at pH 7.4. Loading 
of oocytes with 65Zn-pyrithione, instead of injecting 65Zn, was ineffective and resulted in 
levels of extruded radioactivity that were close to the background of the γ-counter. 
Regarding the amount of 65Zn injected, although the differences are not statistically 
significant, there was a trend to have higher levels of effluxed radioactivity when lower 
amounts of radionuclide were used. 
Regardless of whether the radioactivity was counted in the efflux buffer or in the 
oocytes, analysis of the experiments showed statistically significant 65Zn transport activity of 
the two isoforms but no statistically significant difference in transport activity between the 
two isoforms (Fig. 5).  Preliminary transport activity data also showed no difference between 
W and R variants. 
 
Discussion and Conclusion 
We demonstrate that the long isoform of ZnT8, the one generally used for exogenous 
expression studies of ZnT8, is not only expressed in vesicles but also to a high extent in the 
plasma membrane of HEK293 cells. In contrast to this finding, the long isoforms of ZnT2 and 
ZnT5 were detected in internal membranes and the shorter ones in the cell membrane [21, 
25-28]. Given that we expressed ZnT8 from vectors, it cannot be excluded that the long form 
was mislocalised due to overexpression; nevertheless, the cytolocation of the short form 
expressed in the same manner was mainly intracellular, arguing against such an 
interpretation of the results. We presently do not know if plasma membrane-located ZnT8 is 
exporting zinc from β-cells. However, both isoforms of the protein locate to the cell surface 
when expressed in X. laevis oocytes where they efflux zinc. Other human ZnTs also present 
different isoforms that are either at the plasma membrane or in the membrane of 
organelles, as is the case for ZnT2 and ZnT5 (Table II). Zinc transporters 3, 4, and 7 are 
intracellular transporters and do not have isoforms; ZnT5, 6, and 10 present several possible 
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isoforms, but experimental information on the cellular localization does not exist for some of 
them. 
Human ZnT8 possesses the amino acids that have been shown, by site directed 
mutagenesis, to be important for the function of several CDF members in species such as E. 
coli, Cupriavidus metallidurans, and Populus trichocarpa x Populus deltoides [23], namely 
H52, 54, 106, 220, 304, and 345, S57 and 228, E88 and 276, D103, 110, 224, and 248, and 
G135. According to the classification considering the residues conserved in TMDs II and V 
and the metal ion being transported [23], human ZnT8 clusters with Zn-transporting CDFs. 
Other characteristics of Zn-CDF transporters are also present in human ZnT8: N- and C-
termini rich in histidine and serine residues and histidines in the region between TMDs IV 
and V, the latter ones might be involved in zinc-binding [29, 30]. Remarkably, there is neither 
conservation of the amino acid at position 325 nor of its properties (i.e., hydrophobicity, 
charge, ability to form H-bonds, and presence of aromatic rings): R for human (or W), 
chimpanzee and dog, Q for mouse and rat (for one of the isoforms; the other is only 322-
amino acids long), V for chicken, zebrafish, and E. coli, G for frog, and A for anole, a lizard. 
Additionally, in frog ZnT8 sequences, the zinc ligands in TDMII [31, 32], corresponding to 
positions 106 and 110 (human ZnT8 numbering), are not conserved with the exception of 
histidine 106 in the second isoform, F6T4F9. The di-leucine motif in the C-terminus of 
mammalian ZnT8 sequences, usually associated with clathrin-coated vesicle-mediated 
endocytosis, might be required for the endocytosis of ZnT8 present at the surface of the cell 
following membrane fusion of insulin dense granules (vesicles) and secretion of insulin and 
zinc.  
While two isoforms have been noted for humans, rats, and frogs, there is a lack of 
experimental evidence for other species, either from RNA or protein sequencing data. With 
the exception of the human and rat longer isoforms, ZnT8 from all the species used in the 
alignment are annotated in the Ensembl database as predicted proteins. It needs to be seen 
if ZnT8 is expressed as two isoforms in species from different animal classes.  
Not all mRNA molecules in a cell are translated at a given time; therefore, the 
existence of ZnT8 transcripts encoding two different isoforms does not mean that the cell 
expresses both proteins. The ZnT8 alternative transcripts were detected in an RNAseq 
analysis of human pancreatic islets [13]: the most abundant transcript (71.3%) encodes the 
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longer protein (Q8IWU4_1), while the other (28.7%) encodes the 49-aa shorter one 
(Q8IWU4_2). Current knowledge does not allow conclusions as to whether both or only one 
isoform is expressed.  
Transport activity of human ZnT8 has been investigated employing mainly the longer 
isoform. These investigations, using either 65Zn and isolated β-cell vesicles [17] or fluorescent 
probes and cell lines [7], showed that the R325 variant is less active than the W counterpart. 
However, recently, using a fluorescence-based assay in proteoliposomes, the R variant of the 
shorter isoform turned out to be more active than the W variant [18]. Results are, therefore, 
controversial, or the use of different isoforms might account for the differences. The 
Xenopus oocyte transport assay presents a convenient and well-controlled system to study 
different forms and variants of ZnT8 under exactly the same conditions. A few pilot 
experiments performed in the present study could not detect a difference between the two 
variants, perhaps in agreement with the observation that the type of lipid environment is a 
factor in revealing differences in transport in proteoliposomes [18].  
Uptake and efflux transporters are widely investigated proteins. In the 
pharmaceutical industry, they are important targets for drug design and for understanding 
transport-mediated uptake of drugs and mechanisms of drug resistance. Properties of metal 
transporters have been investigated using a number of systems such as functional 
complementation of Saccharomyces cerevisiae and transport assays in X. laevis oocytes, in 
isolated organelles, in monolayers of cell lines, and in in vitro synthesized lipid vesicles 
containing reconstituted recombinant transporter. Although useful, all these systems have 
drawbacks, such as incorrect protein folding and ambiguity in orientation in the membrane 
after reconstitution in liposomes, lack of endogenous interacting proteins, time-consuming 
and expensive preparation of proteoliposomes, variability of the quality of oocytes, and 
contribution of endogenous transporters. In the specific case of human ZnT8, some of these 
systems have been used, namely assays in β-cell lines, in isolated vesicles, and in 
proteoliposomes. The assays in β-cells are the ones that have an environment closest to the 
native one. However, it is not possible to control every condition in the cell, such as its 
metabolic state and zinc concentration, for instance. Furthermore, zinc transport by variants 
and isoforms introduced into the cell will take place against a background of endogenous 
ZnT8, unless conducted in a cell line where no endogenous ZnT8 is expressed. Transport 
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assays with vesicles isolated from β-cells are a robust experimental system but are limited by 
the amount of material one can obtain as well as background expression of endogenous 
ZnT8. Proteoliposomes can be employed to test various assay conditions, but they constitute 
a very simple system where interacting proteins are missing. In contrast, the X. laevis oocyte 
expression system has not been employed previously to investigate the function of ZnT8, 
though it has been widely used for studies of other transmembrane solute transporters. It 
became possible to employ it for human ZnT8 because we found the protein to be expressed 
at the cell membrane of oocytes. Additionally, the dimers observed in western blots suggest 
that, in oocytes, both ZnT8 isoforms maintain a requisite condition for metal transport 
activity: dimerization. Particularly important for this work is the fact that oocytes do not 
express many endogenous membrane transporters and channels in the latest stage of 
development [24, 33]. These characteristics make X. laevis oocytes an attractive system to 
study functional properties of heterologously expressed transporters. While X. laevis oocytes 
go through six maturation stages, their zinc content increases gradually as the egg yolk 
protein, vitellogenin, incorporates zinc [34], and the zinc content remains constant from 
stage VI of oogenesis until at least stage III of embryogenesis [35]. Therefore, stage VI 
oocytes are a closed system concerning zinc exchange with the environment, and neither 
zinc efflux nor influx is expected to occur through oocyte-specific zinc transporting systems 
and to affect the assay of a heterologously expressed zinc transporter. 
We faced significant variability throughout the assays, which is often observed in 
experiments performed in X. laevis oocytes. The quality of oocytes has been observed to 
undergo seasonal variations and also to vary within a batch of oocytes derived from either 
the same frog or from different frogs [36, 37]. Intra- and inter-experimental variability is also 
affected by the maturation stage of the oocytes as selection depends on visual inspection of 
the eggs. Although the variability among the experiments was high, the results suggest that 
loading of the oocytes is better performed by injecting 65Zn together with NTA, which keeps 
the metal ion in solution. Loading of oocytes with 65Zn using pyrithione takes longer time 
than by injection and, therefore, increases the chances of zinc being compartmentalised 
within the oocytes and less available for efflux by ZnT8. Concerning the tested amounts of 
injected 65Zn (442, 663, or 995 fmol), the assays show better results when the lower 
amounts are used. Considering that oocytes in stage VI of maturation have 70 ng of zinc [37], 
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these cells have about 1000 fmol of zinc; therefore, injection of 442 fmol of zinc increases 
the intracellular concentration of this metal by nearly 50%, and injection of 995 fmol, almost 
doubling and potentially generating considerable stress to the oocyte. The injection of a 
lower concentration of 65Zn could yield better results. For example, when studying iron 
export by ferroportin, injection of a lower concentration of 55Fe led to an increased efflux 
[38]. Injecting less 65Zn to investigate ZnT8 was not possible as our experiments were limited 
by how much 65Zn could be detected by the γ-counter. Regarding the pH of the injected zinc 
solution, a higher pH value promoted more 65Zn transport across the oocyte membrane 
towards the extracellular medium. Also, an efflux buffer without calcium and with NTA at pH 
7.4 is the best condition. Extracellular NTA could be acting as an acceptor akin to insulin in 
the granules, generating an outward concentration gradient. A similar observation was made 
by others [38]: a higher efflux of iron was recorded when apo-transferrin and iron chelators 
were present in the efflux buffer. Concerning the pH value of the extracellular medium, 
given that the intracellular pH of the oocyte is also approximately 7.4 [39] and different 
concentrations of K+ in the buffer did not produce differences in 65Zn efflux, we hypothesize 
that a local increase in proton concentrations is responsible for driving zinc ions in the 
opposite direction, into the extracellular medium. X. laevis oocytes have a Na+/H+ exchanger 
at their membrane, which could fulfil such a function [40]. 
ZnT8 is one of the four islet autoantigens. While its presence on the plasma 
membrane increases when insulin granules fuse with the β-cell plasma membrane during 
glucose induced insulin secretion (GIIS) [12], our findings provide an alternative explanation 
for its presentation at the cell surface. They demonstrate a substantial amount of ZnT8 at 
the plasma membrane in the absence of GIIS. Examination of the N-terminus of the long 
form of ZnT8 with the ELM database predicts ERTYLV (amino acids 5 to 10) as an endosome-
lysosome-basolateral sorting signal (ELME000149) that removes proteins from the plasma 
membrane (Nathan Williams, Dissertation for an MSci degree at King’s College London 
2015). Two types of sorting signals have been described, one of which relates to a 
conditional presence of the protein at the plasma membrane because removal depends on a 
phosphorylation event [41]. The presence of a threonine as well as a tyrosine in the ERTYLV 
sequence suggests that removal of ZnT8 from the plasma membrane depends on the action 
of a yet to be identified kinase.  
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Figure Legends 
Figure 1 – Alignment of the amino acid sequence of human ZnT8 with those of other animals 
and E. coli Yiip (A) and phylogenetic tree (B). A) ZnT8 sequences of amino acids that have 
been shown to be functionally important [23] are denoted with an asterisk (*). Dashed line 
shows the location of the CDF family signature sequence. Grey shaded boxes in TMDs II and 
V highlight the conserved motifs found in Zn-CDF members. Amino acid numbering and 
transmembrane domains (as predicted in the UniProt database) are shown in relation to the 
long isoform of human ZnT8 (Human_1). B) Phylogenetic tree with branch distances. 
Sequences were retrieved from UniProt database. Human_1 and _2 (Homo sapiens): 
Q8IWU4_1 and Q8IWU4_2; Dog (Canis lupus familiaris): F1PTQ3; Mouse (Mus musculus): 
Q8BGG0; Chimpanzee (Pan troglodytes): H2QWL9; Rat_1 and _2 (Rattus norvegicus): P0CE46 
and A0A0H2UHD4; Anole (Anolis carolinensis): G1KKM1; Chicken (Gallus gallus): 
A0A1D5NY81; Zebrafish (Danio rerio): A0A0R4IFM6; Frog_1 and _2 (X. tropicalis): F6W4S9 
and F6T4F9; E. coli Yiip: P69380. The alignment and the phylogenetic tree were performed 
using Clustal Omega. The output of the alignment was visualised by ESPript 3.0 [42]. Amino 
acids conserved in all sequences at a given position are shaded in black. The consensus 
sequence is given: uppercase letters show identity (consensus in 100% of the sequences); 
lowercase letter show consensus in more than 50% of the sequences; ! is any of IV; $ is any 
of LM, and # is any of NDQEBZ. 
Figure 2 - Scheme of the genes cloned into pcDNA3.1(+). In the N-V5-ZnT8lg genes, the V5 
tag was placed after the first 49 amino acids. In both W and R variants of the short isoform, 
the tag was placed in the N-terminus, in the exact same position as in the long isoform. 
Figure 3 – Localization of human ZnT8 isoforms (W325 variant) in HEK293 cells. HEK293 cells 
were transfected with vectors carrying the N-V5-ZnT8lg and the V5-ZnT8sh genes. Proteins 
were detected with anti-V5 tag antibody and the nuclei stained with DAPI. Representative 
experiment out of n=4. 
Figure 4 – Localization of human ZnT8 variants and isoforms in X. laevis oocytes. A and B) 
ZnT8 variants and isoforms are expressed at the surface of oocytes. Xenopus laevis oocytes 
were injected with cRNA for the isoforms and variants of human ZnT8, and localization was 
examined by (A) laser confocal microscopy in whole cells and by (B) western blotting of total 
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(T) and cell-surface biotinylated (B) proteins. ZnT8 proteins were detected with anti-V5 tag 
antibody, and the specificity of biotinylation to cell surface proteins was controlled, upon 
stripping of the membrane, with an antibody against cytosolic GAPDH. Arrow heads indicate 
ZnT8-specific bands. Representative experiment out of n=3. 
Figure 5 – 65Zinc transport assay.  Oocytes were co-injected with 65Zn and 10 mM NTA, 
placed for 1 h in efflux buffer containing 1 mM NTA, at pH 7.4, and the radioactivity in the 
extracellular medium was measured in a γ–counter. Mean ± S.D.; n=4; ***p<0.005. 
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Table I – Conditions tested in 65Zn efflux assays. 
 
 
 
 
 
 
 
 
 
 
Conditions tested 
Loading of oocytes with 65Zn by nano-injection or with 20 µM pyrithione and 50 µM 
65Zn 
Injection of 442, 663, or 995 fmol 65Zn 
Injection of 65Zn at pH 1.1, 3.3, 5.5, or 7 
Injection of 65Zn with 10 mM NTA 
Injection of 9, 18, or 25 ng of N-V5-ZnT8lg or V5-ZnT8sh cRNA 
Presence of 1 mM NTA or 0.1% BSA in the efflux medium, without Ca2+ 
Efflux buffer at pH 5.4 or 7 
Presence of 1, 2.5, or 5 mM K+ in the efflux buffer 
Presence of pyruvate or of bicarbonate in the culture medium 
Pre-culture of oocytes with 0.25, 1, or 5 mM pyruvate 
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Table II – Isoforms and cellular localization of ZnTs. Information was retrieved from human 
ZnTs in the Ensembl database, and only transcripts supported by at least one non-suspect 
mRNA were addressed. Highlighted in grey are data arising from evidence only at the 
transcript level, lacking experimental evidence, or that have not been manually annotated 
and reviewed by UniProtKB curators. Data on the localization of human ZnTs was reviewed 
by Kambe et al. [2], with the exception of ZnT8, which is addressed in this study and by 
Huang et al. [12]. 
 
ZnT 
Isoforms 
(UniProt) 
Predicted N-terminal 
length (aa) and 
number of TMDs 
Protein 
length 
(aa) 
Location in the cell                                           
ZnT1 1 (Q9Y6M5) 9 (6 TMDs) 507 cell membrane 
ZnT2 2 (Q9BRI3) 
90 (5 TMDs) 323 cell membrane 
139 (5 TMDs) 372 internal membranes 
ZnT3 1 (Q99726) 74 (6 TMDs) 388 internal membranes 
ZnT4 1 (O14863) 112 (6 TMDs) 429 internal membranes 
ZnT5 4 (Q8TAD4) 
32 (16 TMDs) 765 internal membranes 
22 (11 TMDs) 523 cell + internal membranes 
32 (2-3 TMDs) 118 unknown 
0 (0 TMDs) 77 unknown 
ZnT6 
3 (Q6NXT4) 
32 (6 TMDs) 461 Internal membranes 
32 (5-6 TMDs) 501 
unknown 
32 (6 TMDs) 438 
4 (6 TMDs) 432 
1 (B5MCR8) 26 (4 TMDs) 387 
ZnT7 1 (Q8NEW0) 36 (6 TMDs) 376 internal membranes 
ZnT8 2 (Q8IWU4) 
30 (6 TMDs) 320 internal membranes 
79 (6 TMDs) 369 cell + internal membranes 
ZnT9 1 (Q6PML9) 238 (5 TMDS) 568 internal membranes 
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ZnT10 3 (Q6XR72) 
10 (6 TMDs) 485 cell + internal membranes 
0 (2 TMDs) 240 unknown 
10 (4 TMDs) 223 unknown 
 
 
 
